The capital is intended for the completion of the ongoing Phase 2 clinical trial of TL-118, for the treatment of metastatic pancreatic cancer
About Moni HorovitzThis author has not yet filled in any details.
So far Moni Horovitz has created 31 blog entries.
Atox Bio Publishes Data Demonstrating the Broad Therapeutic Effect of its Flagship Product in Treating “Flesh Eating Bacteria”
Findings published in the Journal of Infectious Diseases
Avraham Pharmaceuticals Closes an Additional Investment Round of Approximately $6 Million by Yissum, Pontifax and Clal Biotechnology Industries
The capital is intended for the on-going Phase II clinical trial of ladostigil, a novel molecule for treatment of mild cognitive impairment; interim
Tiltan Pharma Announces Enrollment of First U.S. Patient in a Phase 2 Clinical Trial of TL-118, Anti-Angiogenic Treatment for Metastatic Pancreatic Cancer
White Plains Hospital is the first U.S. site
to offer this innovative treatment to cancer patients
Integra Holdings closes U.S. $ 7.0 million private financing
Avraham Pharmaceuticals Announces Commencement of a Phase 2 Study of Ladostigil for the Treatment of MCI
Enrollment has been completed in a Phase 2 study of ladostigil for the treatment of Alzheimer's Disease and results expected in Q4 2012
Jerusalem Israel - February 13, 2012 - Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer.
Yissum, Pontifax, Clal Biotechnology Industries, TRDF and Other Investors Complete Additional Investment Round of $3 Million in Avraham Pharmaceuticals
Yissum will now maintain 30% holding share in Avraham Pharmaceuticals, which will be transferred to its forthcoming biotech holdings company
Atox Bio raises $2.1 Million to advance development of AB103, a novel therapy for the treatment of severe bacterial infections.
Rehovot Israel - October 13, 2010 - Atox Bio Inc. today announced that it has raised $2.1 million to advance the development of AB103, a clinical stage therapeutic being developed for the treatment of severe bacterial infections and sepsis.
Atox Bio, a Spin-Off of Yissum, Announces Dosing of First Subject in Phase 1 study of AB103, a Novel Immunomodulator for the Treatment of Severe Bacterial Infections and Sepsis
Rehovot Israel - September 15, 2010 - Atox Bio, a Spin-Off of Yissum, today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103